<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04696380</url>
  </required_header>
  <id_info>
    <org_study_id>CHRMS 00000555</org_study_id>
    <nct_id>NCT04696380</nct_id>
  </id_info>
  <brief_title>Do Flavors Increase the Addiction Potential of Nicotine?</brief_title>
  <official_title>Do Flavors Increase the Addiction Potential of Nicotine?: A Pilot Laboratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The FDA has concluded that flavors (e.g. menthol) are associated with greater addiction&#xD;
      potential in tobacco cigarettes (Gottlieb March 13, 2019). Whether the same is true for&#xD;
      e-cigarettes and non-menthol flavors is unclear and our study should help answer this&#xD;
      question.&#xD;
&#xD;
      Our major hypothesis is that the pharmacological effect of nicotine to induce addiction will&#xD;
      be greater with use of a preferred e-cigarette flavor than with use of a non-preferred&#xD;
      flavor. The pharmacological effect will be measured by how much a larger nicotine dose&#xD;
      increases addiction potential compared to a smaller dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:&#xD;
&#xD;
      Fifteen participants who currently use e-cigarettes weekly and who use or do not use tobacco&#xD;
      cigarettes will enter a remote session study. Participants will be asked to abstain from all&#xD;
      nicotine/tobacco products, non-nicotine electronic cigarettes, and THC containing products&#xD;
      for 16 hours prior to four experimental sessions and will be tested in a 2x2&#xD;
      within-participants design with four conditions: 1) low nicotine dose (3%)/non-preferred&#xD;
      flavor, 2) low dose/preferred flavor, 3) high dose (5%)/non-preferred flavor, and 4) high&#xD;
      dose/preferred flavor. Order of testing will be randomized. Participants and experimenters&#xD;
      will be blind to dose. The major outcomes will be subjective effects, e.g. liking and tests&#xD;
      of reinforcement (choice procedures). We will require 16 hours of abstinence prior to each&#xD;
      remote experimental session to increase the sensitivity to nicotine effects.&#xD;
&#xD;
      The consent process, experimental sessions and data collection will all be done remotely&#xD;
      using a secure video platform. The only interaction between participants and research staff&#xD;
      will be the curbside pick-up of study products, which will follow social distancing and mask&#xD;
      guidelines. Participants will pick up study JUUL pods curb-side at the University of Vermont&#xD;
      before their baseline videoconference session. Participants will be required to conduct all&#xD;
      videoconference sessions in a place where they can legally use their JUUL.&#xD;
&#xD;
      The consent videoconference session will be conducted prior to the baseline and four&#xD;
      experimental sessions. Participants will be assessed for COVID-19 and E-cigarette or Vaping&#xD;
      Product Use-Associated Lung Injury (EVALI) symptoms prior to the curbside pick-up and at the&#xD;
      start of the 5 videoconference sessions in which they will be asked to vape. During the&#xD;
      baseline session, participants will complete a baseline questionnaire via online survey and&#xD;
      then answer a series of questions about nicotine dependence and how many JUUL pods they would&#xD;
      purchase at varying prices. Participants will then sample the two flavors available for JUUL&#xD;
      -Virginia Tobacco and Menthol- using their own JUUL device. Research staff will ask&#xD;
      participants to rate the pleasantness of each flavor and, after they have tried the flavors,&#xD;
      participants will rank order their flavor preferences to determine their preferred flavor of&#xD;
      the two. Finally, participants will be trained in the puffing protocol to be used in the&#xD;
      experimental sessions.&#xD;
&#xD;
      During each experimental videoconference session, participants will report on their recent&#xD;
      e-cigarette and tobacco product use at the start of each videoconference testing session.&#xD;
      Those reporting non-abstinence will have their videoconference session rescheduled. During&#xD;
      the videoconference testing sessions participants will be asked to puff either tobacco flavor&#xD;
      3% nicotine, tobacco flavor 5% nicotine, menthol flavor 3% nicotine, or menthol flavor 5%&#xD;
      nicotine. After each puffing bout within each session, they will answer questions about about&#xD;
      e-cigarette effects, e-cigarette liking and wanting, like/dislike of e-cigarette taste and&#xD;
      e-cigarette intensity. At the end of each session, they will be asked how many JUUL pods they&#xD;
      would purchase at varying prices.&#xD;
&#xD;
      Adverse events will be collected at the end of each videoconference session by the research&#xD;
      assistant, who will consult with the study licensed medical provider.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Actual">August 31, 2021</completion_date>
  <primary_completion_date type="Actual">August 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liking and wanting nicotine</measure>
    <time_frame>2 weeks</time_frame>
    <description>Average of &quot;I feel good e-cigarette effects&quot;, &quot;I want more of that e-cigarette I received&quot;, &quot;I feel the e-cigarette strength&quot; and &quot;I like the e-cigarette effect&quot; on a 0-100mm scale from &quot;not at all&quot; (0) to &quot;extremely&quot; (100).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>E-cigarette purchase task</measure>
    <time_frame>2 weeks</time_frame>
    <description>This is a modification of the Cigarette Purchase Task that asks how much users would spend to obtain their usual amount of e-liquids to use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>E-cigarette and tobacco cigarette craving</measure>
    <time_frame>2 weeks</time_frame>
    <description>This is a revision of the brief version Questionnaire of Smoking Urges that asks about the presence of urges for e-cigarettes and tobacco cigarettes (0-4 scale, 0= not at all and 4= extremely) and strength of urges (1-5 scale, 1=slight and 5= extremely strong).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Drug Effect Questionnaire</measure>
    <time_frame>2 weeks</time_frame>
    <description>Modified version of the Drug Effects Questionnaire where participants rate acute responses to the e-cigarette drug effects on a 0-100 mm scale, from &quot;not at all&quot; (0) to &quot;extremely&quot; (100).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Labeled Hedonic Scale</measure>
    <time_frame>2 weeks</time_frame>
    <description>1 item about like/dislike of the e-cigarette taste using a modified version of the Labeled Hedonic Scale, a category ratio scale that ranges from -100 (most disliked) to 100 (most liked).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Labeled Magnitude Scale</measure>
    <time_frame>2 weeks</time_frame>
    <description>1 item about e-cigarette taste intensity using a modified version of the Labeled Magnitude Scale, which is a category ratio scale with 7 semantic labels: &quot;no sensation&quot;, &quot;barely detectable&quot;, &quot;weak&quot;, &quot;moderate&quot;, &quot;strong&quot;, &quot;very strong&quot;, and &quot;strongest imaginable&quot;, with responses coded on a 0-100 scale (0= no sensation, 100= strongest imaginable).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>High nicotine, preferred flavor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sample their preferred flavored JUUL e-cigarette at 5% nicotine strength.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High nicotine, non-preferred flavor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sample their non-preferred flavored JUUL e-cigarette at 5% nicotine strength.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low nicotine, preferred flavor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sample their preferred flavored JUUL e-cigarette at 3% nicotine strength.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low nicotine, non-preferred flavor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sample their non-preferred flavored JUUL e-cigarette at 3% nicotine strength.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine</intervention_name>
    <description>Participants will sample high vs low nicotine.</description>
    <arm_group_label>High nicotine, non-preferred flavor</arm_group_label>
    <arm_group_label>High nicotine, preferred flavor</arm_group_label>
    <arm_group_label>Low nicotine, non-preferred flavor</arm_group_label>
    <arm_group_label>Low nicotine, preferred flavor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JUUL e-cigarette</intervention_name>
    <description>Participants will sample preferred vs non-preferred JUUL flavors.</description>
    <arm_group_label>High nicotine, non-preferred flavor</arm_group_label>
    <arm_group_label>High nicotine, preferred flavor</arm_group_label>
    <arm_group_label>Low nicotine, non-preferred flavor</arm_group_label>
    <arm_group_label>Low nicotine, preferred flavor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  21 years or older&#xD;
&#xD;
          -  comfortable reading and writing English&#xD;
&#xD;
          -  own a JUUL brand e-cigarette they have used at least 10 times in the past 30 days&#xD;
&#xD;
          -  use JUUL e-cigarettes and JUUL pods with 5% nicotine&#xD;
&#xD;
          -  used e-cigarettes on 4+ days a week in the last 30 days&#xD;
&#xD;
          -  use or do not use tobacco cigarettes&#xD;
&#xD;
          -  do not plan to quit e-cigarettes in the next 30 days&#xD;
&#xD;
          -  non-pregnant females verified by pregnancy test&#xD;
&#xD;
          -  access to the internet in a location where they could join a videoconference call and&#xD;
             legally use their JUUL.&#xD;
&#xD;
          -  Reside in VT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John R Hughes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>John Hughes, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

